Reading NRIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRIX free→Reading NRIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRIX free→QuarterlyIQ Insights · NRIX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On June 7, 2026, Nurix issued a press release announcing (i) Nurix’s entry into the Collaboration Agreement and (ii) that on June 8, 2026, at 8:00 a.m. Eastern Time, Nurix will host a conference call and webcast to discuss the collaboration between Nurix and Roche. The live webcast, with an accompanying presentation, will be accessible under the Events and Presentations page in the Investors section of Nurix’s website. A replay of the call and webcast will be archive…
Entry into a Material Definitive Agreement. On June 6, 2026, Nurix Therapeutics, Inc. (“ Nurix ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “ Roche ”), pursuant to which Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights to develop, manufacture, commercial…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.